Iloprost Pharmamentum

Iloprost Trometamol, the active ingredient in Iloprost Pharmamentum, is a prostacyclin analog presented as a intravenous solution for intravenous use. It treats pulmonary arterial hypertension and related vascular conditions in adult patients.\n\nGNH India supplies Iloprost Pharmamentum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Iloprost Pharmamentum, a prostacyclin analog, is used in conditions involving pulmonary vascular dysfunction.\n\nPulmonary arterial hypertension: lowers pulmonary arterial pressure, improves exercise capacity and functional class.\nDigital ulcers: enhances microvascular blood flow to promote healing of ischemic skin lesions.\nRaynaud's phenomenon: reduces frequency and severity of vasospastic attacks by dilating peripheral arteries.

Iloprost may cause a range of adverse reactions, from mild to severe.\n\nCommon Side Effects:\n- Headache: transient throbbing pain often occurring during infusion.\n- Flushing: warm sensation and reddening of the skin, especially on the face and neck.\n- Nausea: mild gastrointestinal upset that may resolve with continued therapy.\n- Hypotension: modest drop in blood pressure, usually manageable.\n- Jaw pain: discomfort in the mandibular area during infusion.\n\nSerious or Rare Side Effects:\n- Severe hypotension: marked blood pressure decline requiring medical intervention.\n- Pulmonary edema: accumulation of fluid in the lungs presenting with dyspnea.\n- Bleeding complications: increased risk of hemorrhage due to platelet inhibition.\n- Thrombocytopenia: significant reduction in platelet count.\n- Cardiac arrhythmias: irregular heart rhythms that may be life‑threatening.

When using Iloprost Pharmamentum, clinicians should observe several safety measures.\n\nMonitor blood pressure: check regularly during and after infusion.\nAssess bleeding risk: avoid in patients with active hemorrhage or severe coagulopathy.\nAdjust dose in renal impairment: consider reduced clearance in severe kidney dysfunction.\nAvoid concomitant potent vasodilators: may amplify hypotensive effects.\nUse under specialist supervision: administration should be managed by experienced healthcare professionals.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iloprost can interact with other medicines, requiring careful management.\n\nMajor Interactions (Avoid):\n- Potent vasodilators (e.g., nitroglycerin): may cause dangerous hypotension.\n- Anticoagulants (e.g., warfarin, heparin): increased risk of bleeding.\n- Endothelin receptor antagonists: additive pulmonary vasodilatory effect.\n\nModerate Interactions (Monitor Closely):\n- Calcium channel blockers: may enhance vasodilatory response.\n- Aspirin or other antiplatelet agents: monitor for excessive bleeding.\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect renal function and platelet activity.